Kowa Company,Ltd. (Headquarters:Nagoya, Aichi Prefecture, Japan), today announced an upcoming presentation of non-clinical data for K-679, its novel antibody drug-loaded unimicelle conjugate (ADUC) with unprecedented drug loading capacity. The compound, developed using Kowa's proprietary micelle technology, has demonstrated superior efficacy in EGFR-expressing solid tumors compared to conventional antibody drug conjugates (ADCs). The data will be presented at The American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25th-30th, 2025 in Chicago, Illinois.
https://mma.prnewswire.com/media/320297/kowa_research_institute_inc_logo.jpg
Presentation DetailsPresentation Title: K-679: A novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs.Session Title: Novel Drug Delivery TechnologiesPresentation Date and Time: April 28, 2025, 9:00 a.m. – 12:00 p.m. CST (10:00 a.m. – 1:00 p.m. ET)Published Abstract Number:1798Presenter: Hideo Yoshida
The abstract of the presentation is available athttps://www.abstractsonline.com/pp8/#!/20273/presentation/3006.
More information about the AACR Annual Meeting 2025 can be found on the event website at the following link: AACR Annual Meeting 2025 | Meetings | AACR
About K-679K-679is an Antibody Drug-loaded Unimicelle Conjugate (ADUC), a novel type of ADC using Kowa's proprietary micelle technology, currently at non-clinical stage. The conjugate combines ananti-EGFR antibody with drug (DM1)-loaded unimicelles, which incorporate substantial quantities of payloads into a single-chain polymer. This innovative approach achieves an ultra-high DAR (Drug-to-Antibody Ratio) of approximately 40 DM1 molecules per antibody, significantly higher than conventional ADCs.
In non-clinical studies, K-679 has demonstrated potent anti-tumor effects in xenograft models, outperforming conventional ADCs. Notably, K-679 has shown remarkable efficacy in EGFR‑positive and -negative heterogeneous tumors, exhibiting significant bystander killing effects.
Media Contact:Ian MehrKowa Research Institute, Inc.919-433-1600imehr@kowaus.com
https://c212.net/c/img/favicon.png?sn=CL64563&sd=2025-04-21
View original content to download multimedia:https://www.prnewswire.com/news-releases/k-679-a-novel-antibody-drug-loaded-unimicelle-conjugate-with-ultra-high-drug-loading-capacity-demonstrates-superior-efficacy-in-egfr-expressing-solid-tumors-302428078.html
SOURCE Kowa Company Ltd.
https://rt.newswire.ca/rt.gif?NewsItemId=CL64563&Transmission_Id=202504211000PR_NEWS_USPR_____CL64563&DateId=20250421